AA
PCVX icon

ALPS Advisors’s Vaxcyte PCVX Stock Holding History

ALPS Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60,964
Closed -$2.2M – 1065
2025
Q3 		$2.2M Sell
60,964
-8,650
-12% -$287K 0.01% 360
2025
Q2 		$2.26M Buy
+69,614
New +$2.28M 0.01% 351
2024
Q2 		– Sell
-76,316
Closed -$5.21M – 991
2024
Q1 		$5.21M Buy
76,316
+11,021
+17% +$763K 0.04% 233
2023
Q4 		$4.1M Sell
65,295
-4,010
-6% -$208K 0.03% 240
2023
Q3 		$3.53M Buy
69,305
+426
+0.6% +$21K 0.03% 244
2023
Q2 		$3.44M Buy
68,879
+16,153
+31% +$766K 0.03% 228
2023
Q1 		$1.98M Sell
52,726
-881
-2% -$37.4K 0.02% 292
2022
Q4 		$2.57M Buy
53,607
+21,196
+65% +$832K 0.02% 255
2022
Q3 		$778K Sell
32,411
-2,184
-6% -$55.4K 0.01% 516
2022
Q2 		$753K Buy
+34,595
New +$801K 0.01% 516

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ALPS Advisors's PCVX Position: Q4 2025 in Review

ALPS Advisors sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 60,964 shares — an estimated $2.2M sold.

ALPS Advisors first reported a position in PCVX in Q2 2022 and held it in 10 quarters. The position peaked at $5.21M in Q1 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • ALPS Advisors reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 60,964 Vaxcyte shares in Q4 2025, an estimated $2.2M.
  • ALPS Advisors first reported a position in Vaxcyte in Q2 2022 and held it in 10 quarters.
  • ALPS Advisors's Vaxcyte position peaked at $5.21M in Q1 2024.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.